Drug Type Small molecule drug |
Synonyms 安纳拉唑钠, KBP 3571, KBP-3571 + [1] |
Target |
Mechanism Proton pump inhibitors |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date CN (21 Jun 2023), |
RegulationSpecial Review Project (CN) |
Molecular FormulaC21H23N2NaO4S |
InChIKeyLHPWFLYRYFEIBN-UHFFFAOYSA-N |
CAS Registry- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Duodenal Ulcer | CN | 21 Jun 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Esophagitis, Peptic | Phase 2 | CN | 01 Dec 2022 | |
Gastroesophageal Reflux | Phase 2 | CN | 01 Dec 2022 | |
Helicobacter pylori infection | Phase 1 | CN | 10 Aug 2020 | |
Helicobacter pylori infection | Phase 1 | CN | 10 Aug 2020 | |
Stomach Ulcer | Phase 1 | CN | 14 Aug 2014 |
Phase 3 | 448 | jizyoijeui(wnhxutkckp) = cyiqfaijzb ngqokaprro (jhyjqgkttv ) | Positive | 30 Dec 2022 | |||
jizyoijeui(wnhxutkckp) = kmgdsvqiwm ngqokaprro (jhyjqgkttv ) | |||||||
Phase 2 | 150 | Rabeprazole 10 mg | yqfsrpjlpx(ruuukvjdyh) = The incidence rates of adverse events were of no significant differences among the treatment groups mouzfggqrn (febimnpwxc ) View more | Positive | 01 Jan 2021 | ||